ClinChoice is a mid-size, global, full-service contract research organization (CRO) that helps pharmaceutical, biotech, medical device, and consumer health companies run clinical trials and bring drugs and devices to market. Founded in 1995 and headquartered in Horsham, Pennsylvania, the firm employs roughly 4,000 people across the Americas, Europe, and Asia-Pacific, offering clinical development, biometrics, safety/pharmacovigilance, regulatory affairs, post-marketing real-world evidence, and technology services. After rebranding from Fountain Medical Development (FMD K&L) in 2020 and raising a $150M Series E in 2022, ClinChoice has grown through acquisitions to serve six of the top ten pharma companies while focusing on emerging and mid-size biotech innovators.
Sean P. Bohen is President and CEO of Olema Oncology, a San Francisco clinical-stage biopharmaceutical company developing targeted therapies for women's cancers. An MD/PhD oncologist who spent 13 years at Genentech and four as AstraZeneca's Chief Medical Officer, he is now steering Olema's lead drug palazestrant - an oral complete estrogen receptor antagonist - through Phase 3 trials in ER+/HER2- metastatic breast cancer.
Steven Basta is the President and CEO of Phathom Pharmaceuticals (NASDAQ: PHAT), a commercial-stage biopharmaceutical company focused on gastrointestinal disorders. He joined in April 2025 to lead the commercialization of VOQUEZNA (vonoprazan), a next-generation potassium-competitive acid blocker for GERD and H. pylori. With more than 25 years of biopharma and medical device leadership spanning BioForm Medical, Merz Aesthetics, AlterG, Menlo Therapeutics, Mahana Therapeutics, and SaNOtize, Basta brings a track record of building and launching products in highly competitive markets. He trained as a biomedical engineer at Johns Hopkins and later earned his MBA from Northwestern's Kellogg School.
Steve Herne is the CEO of Unlearn.AI, a San Francisco-based company building AI-powered digital twin technology to transform how clinical trials are designed and run. With over 25 years of experience across pharmaceutical R&D companies including WCG, Bioclinica, and Covance, Herne joined Unlearn in May 2024 as Chief Commercial Officer before ascending to CEO in September 2024. Under his leadership, Unlearn — backed by $130M+ in venture funding including a $50M Series C led by Altimeter Capital — is pivoting from research-led to commercially-driven product delivery, with its digital twin models now EMA-qualified and adopted by major biopharma companies to reduce placebo arm sizes by up to 38% in pivotal trials.
Jorge F. DiMartino, M.D., Ph.D., is Chief Medical Officer and Executive Vice President of Clinical and Translational Development at Plexium, a San Diego-based biotech pioneering targeted protein degradation. A physician-scientist trained in genetics, immunology, and pediatric oncology across UC Berkeley, Cornell, UC San Diego, and Stanford, DiMartino has spent over two decades advancing cancer drugs from bench to bedside. His fingerprints are on three now-marketed therapies: vismodegib, venetoclax, and enasidenib - each a breakthrough in its own right. At Plexium, he oversees clinical programs targeting SMARCA2, IKZF2, CDK2, and CRAF using the company's DELTA Discovery platform, a novel approach to degrading proteins previously considered undruggable.